Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin).
Esgliteo is its smaller tablet size, measuring approximately 8.1 millimetres. This size is intended to enhance convenience for patients who struggle with swallowing larger pills. Additionally, Esgliteo offers two dosage options to cater to patients in need of additional glycaemic control: 10 mg of empagliflozin combined with 5 mg of linagliptin, or 25 mg of empagliflozin with 5 mg of linagliptin.
Esgliteo brings several benefits as a combination therapy. Firstly, it delivers a superior glucose-lowering effect compared to either medication used alone. In the EMPA-REG OUTCOME study, empagliflozin, the SGLT-2 inhibitor component, demonstrated a significant cardiovascular benefit by reducing the risk of major cardiovascular events (cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to a placebo.
Esgliteo harnesses the complementary mechanisms of SGLT-2 and DPP-4 inhibitors to achieve enhanced glucose control. In a phase 3 study, Esgliteo exhibited improved glycemic control at week 24 when compared to using empagliflozin or linagliptin alone as monotherapies.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!